Measuring Fatty Acid Oxidation in Cerebral Metastases Using [18F]FPIA

Inclusion Criteria:

A) Treatment naïve

or

B) SRS+/- combination treated - Patients that have completed the SRS part of a combination regime enabling a 4-8 week post-SRS treatment PET/MRI scan.

and

C) That fulfil the following criteria:

1. Age ≥18.

2. Target metastases size ≥ 1cm.

3. WHO performance status 0 - 2.

4. If female, the subject is either post-menopausal (at least 1 year), or surgicallysterilized (has had a documented bilateral oophorectomy and/or documentedhysterectomy for at least 2 years), or if of childbearing potential, must have anegative urine beta human chorionic gonadotropin (beta-hCG) pregnancy test doneprior to tracer administration.

5. The subject is able and willing to comply with study procedures, and signed anddated informed consent is obtained.

6. The subject has a satisfactory medical history as judged by the investigator with nosignificant co-morbidities.

7. The subject's clinical and laboratory tests are within normal limits and/orconsidered clinically insignificant.

Exclusion Criteria:

1. The subject is pregnant or lactating.

2. Any other chronic illness that will or musculoskeletal condition that would notallow comfortable performance of a PET study.

3. Prior use within 14 days of enrolment or concurrent therapy with any otherinvestigational agent.

4. Unsatisfactory renal function (eGFR<30).

5. The subject has non-MRI compatible devices (e.g.a pacemaker, an implantablecardioverter-defibrillator (ICD), a nerve stimulator, a cochlear implant or a drugpump) or implanted material (e.g. non-MRI compatible sternal wires, biostimulators,metals or alloys).